Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082298" target="_blank" >RIV/00216224:14110/15:00082298 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00062983

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.fertnstert.2014.10.038" target="_blank" >http://dx.doi.org/10.1016/j.fertnstert.2014.10.038</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.fertnstert.2014.10.038" target="_blank" >10.1016/j.fertnstert.2014.10.038</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

Popis výsledku v původním jazyce

Objective: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily of ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. Design: Double-blind, randomized administration of two 12-week courses ofulipristal acetate. Setting: Gynecology centers. Patient(s): A total of 451 patients with symptomatic uterine fibroid(s) and heavy bleeding. Intervention(s): Two repeated 12-week treatment courses of daily 5 or 10 mg of ulipristal acetate. Main Outcome Measure(s): Amenorrhea, controlled bleeding, fibroid volume, quality of life (QoL), pain. Result(s): In the 5- and 10-mg treatment groups (62% and 73% of patients, respectively) achieved amenorrhea during both treatment courses. Proportions of patients achieving controlled bleeding during two treatment courses were &gt;80%. Menstruation resumed after each treatment course and was diminished compared with baseline.

Název v anglickém jazyce

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

Popis výsledku anglicky

Objective: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily of ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. Design: Double-blind, randomized administration of two 12-week courses ofulipristal acetate. Setting: Gynecology centers. Patient(s): A total of 451 patients with symptomatic uterine fibroid(s) and heavy bleeding. Intervention(s): Two repeated 12-week treatment courses of daily 5 or 10 mg of ulipristal acetate. Main Outcome Measure(s): Amenorrhea, controlled bleeding, fibroid volume, quality of life (QoL), pain. Result(s): In the 5- and 10-mg treatment groups (62% and 73% of patients, respectively) achieved amenorrhea during both treatment courses. Proportions of patients achieving controlled bleeding during two treatment courses were &gt;80%. Menstruation resumed after each treatment course and was diminished compared with baseline.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FK - Gynekologie a porodnictví

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Fertility and Sterility

ISSN

0015-0282

e-ISSN

—

Svazek periodika

103

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

519-527

Kód UT WoS článku

000348966700035

EID výsledku v databázi Scopus

—